leisure time -WSS

leisure time

author：leisure time 2025-09-29 22:36:31 - browse：73

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： European officials brace for rough respiratory virus season

leisure time

WSS

Fetal cell organoids grown from amniotic fluid, study finds

Longer MASH drug regimen improved liver, Akero study finds

Nobel honors Karikó and Weissman's enduring partnership

For AI in health care standards, federal regulators join with industry group

A new approach to psychiatric drug development

WHO recommends second malaria vaccine

focus

leisure time

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

The United States is paying nearly triple for new Covid vaccines

Cancer drug shortages should be causing more outrage

Stem cell biologist probes earliest stages of human development

FDA approval of Sarepta Duchenne genetic therapy gives me hope

State of the Union pitch: Bigger Medicare drug price negotiations

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The biotech scorecard for Q4: 16 stock

focus

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Longer MASH drug regimen improved liver, Akero study finds

Biden's 'march

Medicare drug price negotiation hearing pits pharma v Biden admin

Ozempic has benefits for kidney disease as well as diabetes

Ozempic has benefits for kidney disease as well as diabetes

focus

explore

leisure time

knowledge